Clinical Trial Update: Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tislelizumab combined with chemotherapy as neoadjuvant therapy for locally advanced, resectable head and neck squamous cell carcinoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Head &Amp; Neck Squamous Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING